Prevalence of EGFR T790M mutation in NSCLC patients after afatinib failure, and subsequent response to osimertinib

被引：0
|
作者：
Hochmair, Maximilian [1 ,2 ]
Schwab, Sophia [1 ,2 ]
Burghuber, Otto [1 ,2 ]
Koger, Renate [1 ,2 ]
Setinek, Ulrike [1 ,2 ]
Cseh, Agnieszka [1 ,2 ]
Fritz, Richard [1 ,2 ]
Buder, Anna [3 ]
Filipits, Martin [3 ]
机构：
[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[2] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
[3] Med Univ Vienna, Inst Canc Res, Dept Med 1, Comprehens Canc Ctr, Vienna, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2017年 / 129卷 / 19-20期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P55
引用
收藏
页码：776 / 776
页数：1
相关论文
共 50 条
  • [41] First experience with osimertinib in patients with T790M mutation previously treated with EGFR TKIs in Croatia.
    Jakopovic, Marko
    Bitar, Lela
    Cucevic, Branka
    Plestina, Sanja
    Mazuranic, Ivica
    Seiwerth, Sven
    Hecimovic, Ana
    Dugac, Andrea Vukic
    Jankovic, Mateja
    Redzepi, Gzim
    Samarzija, Miroslav
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] T790M Mutation and Clinical Outcomes with Genuine Osimertinib
    Parikh, Purvish M.
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (01) : 7 - 8
  • [43] Adjusted Indirect Comparison of Osimertinib to Chemotherapy in NSCLC Patients with EGFRm T790M Who Progressed after EGFR-TKI
    Hoyle, C.
    Andersohn, F.
    Mitsudomi, T.
    Mok, T.
    Yang, J. C.
    Green, M.
    Mann, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1849 - S1850
  • [44] EGFR T790M mutation testing within the osimertinib AURA Phase I study
    Dearden, Simon
    Brown, Helen
    Jenkins, Suzanne
    Thress, Kenneth S.
    Cantarini, Mireille
    Cole, Rebecca
    Ranson, Malcolm
    Janne, Pasi A.
    LUNG CANCER, 2017, 109 : 9 - 13
  • [45] Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
    Passaro, Antonio
    Guerini-Rocco, Elena
    Pochesci, Alessia
    Vacirca, Davide
    Spitaleri, Gianluca
    Catania, Chiara Matilde
    Rappa, Alessandra
    Barberis, Massimo
    de Marinis, Filippo
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 406 - 415
  • [46] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
    Zhengquan Yang
    Jialu Li
    Yujie Hu
    Meihua Chen
    Danli Peng
    Dan Zong
    Qingjuan Shang
    Lianqin Tao
    Yanling Zhao
    Yiyun Ni
    Jinyan Ye
    Yupeng Xie
    Li Yang
    Quan Lin
    Chang Cai
    Ning Xu
    Xiaoping Huang
    Xiaoting Dong
    Zhonghui Zhou
    Yali Yu
    Zongxiao Shangguan
    Yangyang Xu
    Weiping Ying
    Meiling Weng
    Zuguo Yuan
    Zhijun Dong
    Jifa Li
    Zhe Zheng
    Jiongwei Pan
    Lu Liu
    Junhui Ye
    Zhan Zhang
    Wenfeng Li
    Junfei Zhu
    Shengnan Jin
    Yuping Li
    Chunming Ding
    Targeted Oncology, 2019, 14 : 719 - 728
  • [47] Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC
    Hwang, Ji An
    Choi, Chang-Min
    Lee, Jae Cheol
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [48] Intracranial Activity of Osimertinib in Naive EGFRm T790M(-) And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
    Peled, N.
    Nechushtan, H.
    Ilouze, M.
    Dudnik, E.
    Inbar, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
  • [49] Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
    Kuiper, J. L.
    Heideman, D. A. M.
    Thunnissen, E.
    Paul, M. A.
    van Wijk, A. W.
    Postmus, P. E.
    Smit, E. F.
    LUNG CANCER, 2014, 85 (01) : 19 - 24
  • [50] Detection of EGFR T790M mutation by ddPCR in untreated NSCLC patients: Correlation with clinical outcome
    Ganzinelli, Monica
    Rulli, Eliana
    Tamborini, Elena
    Busico, Adele
    Lo Russo, Giuseppe
    Corrao, Giulia
    Vitali, Milena
    Garassino, Marina Chiara
    Broggini, Massimo
    Marabese, Mirko
    CANCER RESEARCH, 2017, 77
12345